Serendeputy - your personal news assistant.

Welcome to Serendeputy!

Serendeputy is your personal news assistant.

Your deputy:
- learns what you like and don't like,
- lovingly compiles a list of news and blogs for you.

You can help your deputy learn by searching, clicking links and pressing the little smiley faces.
How it works.

What to do:
  1. Click links to teach your deputy
  2. Click smileys and frownies
  3. Find favorite topics and sources
  4. See how much better your deputy is getting at finding you good stuff.
  5. Sign in for free to save your profile, or please tell me why you won't.
For those looking to get away from the broader biotech indices’ plummet this week (the Nasdaq Biotechnology Index (NASDAQ: IBB) fell 7 percent), we’ve got your comfort food here: a feature about gene therapy’s long quest to cure hemophilia, a scientific...
From: Xconomy | By: Ben Fidler | Friday, March 27, 2015
Derek writes: As a scientist in the biopharma world, I can tell you this this does indeed seem very close to being done in humans, and that there is a very high (but still not perfect) chance of success. CRISPR/Cas9 is the real deal, and there are others...
From: Marginal Revolution | By: Tyler Cowen | Thursday, March 26, 2015
Jennifer Doudna of the University of California, Berkeley, led the group of 18 scientists who published a letter last week in Science magazine calling for urgent discussions on efforts to change the DNA of sperm, eggs, and embryos—known collectively...
From: Xconomy | By: Alex Lash | Friday, March 27, 2015
With claims of better success rates, pioneering treatments and cheaper IVF, foreign clinics are cleaning up. So are 'fertility tourists' getting a better deal?...
From: Telegraph | By: Anna Magee | Saturday, March 28, 2015